Phase II, Open Label, Randomized, Two Treatment Groups, Study Assessing Pharmacokinetics After Administration of the Once Weekly and Once Monthly, Long Acting Subcutaneous Injection of CAM2038 in Opioid Dependent Subjects With Chronic Pain

Trial Profile

Phase II, Open Label, Randomized, Two Treatment Groups, Study Assessing Pharmacokinetics After Administration of the Once Weekly and Once Monthly, Long Acting Subcutaneous Injection of CAM2038 in Opioid Dependent Subjects With Chronic Pain

Active, no longer recruiting
Phase of Trial: Phase II

Latest Information Update: 12 Jul 2017

At a glance

  • Drugs Buprenorphine (Primary)
  • Indications Opioid abuse; Pain
  • Focus Pharmacokinetics
  • Sponsors Braeburn Pharmaceuticals
  • Most Recent Events

    • 12 Jul 2017 Topline results published in the Braeburn Pharmaceutical media Release.
    • 07 Oct 2016 Planned End Date changed from 1 Sep 2016 to 1 Mar 2017.
    • 07 Oct 2016 Planned primary completion date changed from 1 Sep 2016 to 1 Mar 2017.
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top